Leukemia and Lymphoma : Impact Factor & More
eISSN: 1029-2403pISSN: 1042-8194
Share this on:
Key Metrics
CiteScore 
4.2
Impact Factor
< 5
SNIP
0.79
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Leukemia and Lymphoma Journal Specifications
Indexed in the following public directories
Scopus 
SJR
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1989 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Leukemia and Lymphoma ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Leukemia and Lymphoma
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
- 26 Jun 2026
- Leukemia & Lymphoma
Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population
- 25 Jun 2026
- Leukemia & Lymphoma
Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study
- 25 Jun 2026
- Leukemia & Lymphoma
T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma
- 24 Jun 2026
- Leukemia & Lymphoma
Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis
- 23 Jun 2026
- Leukemia & Lymphoma
Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL
- 23 Jun 2026
- Leukemia & Lymphoma
D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison
- 26 Jun 2026
- Leukemia & Lymphoma
Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population
- 25 Jun 2026
- Leukemia & Lymphoma
Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study
- 25 Jun 2026
- Leukemia & Lymphoma
T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma
- 24 Jun 2026
- Leukemia & Lymphoma
Association between interleukin-10 (IL-10) genetic polymorphisms and non-hodgkin lymphoma: a systematic review and meta-analysis
- 23 Jun 2026
- Leukemia & Lymphoma
Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL
- 23 Jun 2026
- Leukemia & Lymphoma
FAQs on Leukemia and Lymphoma
How long has Leukemia and Lymphoma been actively publishing? 
What is the publishing frequency of Leukemia and Lymphoma?
How many articles did Leukemia and Lymphoma publish last year?
What is the eISSN & pISSN for Leukemia and Lymphoma?
What is Citescore for Leukemia and Lymphoma?
What is SNIP score for Leukemia and Lymphoma?
Who is the publisher of Leukemia and Lymphoma?
